Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 4/20 | 0.73 |
| ▸ | TRPV1 | Q8NER1 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2628747 | 1.00 | TRPM8 (0.73) | TRPM8TRPV1RAB9APOLBHTT | |
| SCHEMBL10073506 | 0.90 | TRPM8 (0.73) | TRPM8TRPV1RAB9APOLBNPSR1 | |
| SCHEMBL4820732 | 0.88 | TRPM8 (0.75) | TRPM8TRPV1RAB9AHTTEPHX1 | |
| SCHEMBL4817319 | 0.88 | TRPM8 (0.75) | TRPM8TRPV1RAB9AEPHX1NPC1 | |
| SCHEMBL10073486 | 0.88 | TRPM8 (0.75) | TRPM8TRPV1RAB9AHTTEPHX1 | |
| SCHEMBL2628672 | 0.88 | TRPM8 (0.75) | TRPM8TRPV1RAB9AEPHX1NPC1 | |
| SCHEMBL14593913 | 0.87 | TRPM8 (0.73) | TRPM8TRPV1RAB9APOLBEPHX1 | |
| SCHEMBL2628758 | 0.87 | TRPM8 (0.73) | TRPM8TRPV1RAB9AEPHX1NPC1 | |
| SCHEMBL2628777 | 0.87 | TRPM8 (0.73) | TRPM8TRPV1RAB9APOLBEPHX1 | |
| SCHEMBL4820314 | 0.87 | TRPM8 (0.73) | TRPM8TRPV1RAB9APOLBEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7417048-B2 | Aryl-substituted derivatives of cycloalkyl and branched chain alkyl carboxylic acids useful as antinociceptive drugs for peripheral targets | WEI EDWARD T | 2008-08-26 | — | — | US | disclosed |
| US-20070053834-A1 | Radioligands for the TRP-M8 receptor and methods therewith | WEI EDWARD T | 2007-03-08 | — | — | US | disclosed |
| US-20050187211-A1 | N-arylsalkyl-carboxamide compositions and methods | WEI EDWARD T (US) | 2005-08-25 | — | — | US | disclosed |
| US-20050159394-A1 | Aryl-substituted derivatives of cycloalkyl and branched chain alkyl carboxylic acids useful as antinociceptive drugs for peripheral targets | WEI EDWARD T (US) | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187211-A1 | N-arylsalkyl-carboxamide compositions and methods | OPRL1, TRPV1, TRPA1 | TRPM8 13/4885TRPV1 2/4885RAB9A 2610/4885 |
| US-20070053834-A1 | Radioligands for the TRP-M8 receptor and methods therewith | GPR68, TRPM8, OPRL1 | TRPM8 2/4885TRPV1 10/4885RAB9A 2137/4885 |
| US-20050159394-A1 | Aryl-substituted derivatives of cycloalkyl and branched chain alkyl carboxylic acids useful as antinociceptive drugs for peripheral targets | OPRL1, OPRK1, OPRD1 | TRPM8 588/4885TRPV1 25/4885RAB9A 4208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.